Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06108219 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
A Phase 2 study of Nonalcoholic Steatohepatitis (NASH) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), sponsored by Corcept Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
- 20
- Study locations
NCT06108219 is a Phase 2 study of Nonalcoholic Steatohepatitis (NASH) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is active but no longer recruiting, run by Corcept Therapeutics. The registered enrollment target is 175 participants, above the 99-participant average among 6 other Nonalcoholic Steatohepatitis (NASH) trials with a reported enrollment target (77% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT06108219, a Phase 2 study of Nonalcoholic Steatohepatitis (NASH) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), is active but no longer recruiting, sponsored by Corcept Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)
Conditions Studied
Interventions
- DRUG Miricorilant (Cohort A)
- DRUG Placebo (Cohort A)
- DRUG Miricorilant (Cohort B)
- DRUG Placebo (Cohort B)
Study Locations (20)
Florida
- Site #452 - Boca Raton
- Site # 101 - Gainesville
- Site #465 - Hallandale
- Site #430 - Hialeah Gardens
- Site #458 - Lakewood Rch
- Site #475 - Largo
- Site #438 - Miami Lakes
- Site #460 - Viera
California
- Site #378 - Huntington Park
- Site #439 - Lancaster
- Site #469 - Long Beach
- Site #373 - Los Angeles
- Site #214 - Panorama City
- Site #233 - Santa Ana
Louisiana
- Site #453 - Houma
- Site #451 - Marrero
- Site #061 - Metairie
Arizona
- Site #207 - Chandler
- Site #209 - Tucson
Maryland
- Site #440 - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06108219
The ClinicalTrials.gov registry entry for NCT06108219 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 99-participant average among 6 other Nonalcoholic Steatohepatitis (NASH) trials with a reported enrollment target (77% higher). The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Nonalcoholic Steatohepatitis (NASH) appearing as the primary indexed condition, and to 4 interventions - of which Miricorilant (Cohort A) is the first listed.
NCT06108219 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06108219 about?
NCT06108219 is a clinical study titled "A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)". A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)
What is the current status of trial NCT06108219?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2023-10-25. Estimated completion is 2026-09.
What conditions does trial NCT06108219 study?
This clinical trial studies the following conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH).
What interventions are being tested in trial NCT06108219?
The interventions under investigation include: Miricorilant (Cohort A) (DRUG), Placebo (Cohort A) (DRUG), Miricorilant (Cohort B) (DRUG), Placebo (Cohort B) (DRUG).
Who is sponsoring clinical trial NCT06108219?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06108219 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonalcoholic Steatohepatitis (NASH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH
COMPLETED · Phase 2
-
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
COMPLETED · Phase 2
-
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
RECRUITING · Phase 1
-
Tesamorelin Effects on Liver Fat and Histology in HIV
COMPLETED · NA
-
Feasibility of VIIT in Adults With NASH
COMPLETED · NA
Explore more on PlainTrial
Nonalcoholic Steatohepatitis (NASH)
All registered trials for this condition
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.